PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Christian Blank, Ian Elliott Brown, Amy C. Peterson, Mike Spiotto, Yoshiko Iwai, Tasuku Honjo, Thomas F. Gajewski

Research output: Contribution to journalArticle

477 Citations (Scopus)

Abstract

Although increased circulating tumor antigen-specific CD8+ T cells can be achieved by vaccination or adoptive transfer, tumor progression nonetheless often occurs through resistance to effector function. To develop a model for identifying mechanisms of resistance to antigen-specific CTLs, poorly immunogenic B16-F10 melanoma was transduced to express the K b-binding peptide SIYRYYGL as a green fluorescent protein fusion protein that should be recognized by high-affinity 2C TCR transgenic T cells. Although B16.SIY cells expressed high levels of antigen and were induced to express Kb in response to IFN-γ, they were poorly recognized by primed 2C/RAG2-/- T cells. A screen for candidate inhibitory ligands revealed elevated PD-L1/B7H-1 on IFN-γ-treated B16-F10 cells and also on eight additional mouse tumors and seven human melanoma cell lines. Primed 2C/RAG2-/-/PD-1-/- T cells showed augmented cytokine production, proliferation, and cytolytic activity against tumor cells compared with wild-type 2C cells. This effect was reproduced with anti-PD-L1 antibody present during the effector phase but not during the priming culture. Adoptive transfer of 2C/RAG2-/-/PD-1-/- T cells in vivo caused tumor rejection under conditions in which wild-type 2C cells or CTLA-4-deficient 2C cells did not reject. Our results support interfering with PD-L1/PD-1 interactions to augment the effector function of tumor antigen-specific CD8+ T cells in the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)1140-1145
Number of pages6
JournalCancer Research
Volume64
Issue number3
DOIs
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
T-Lymphocytes
Neoplasms
Adoptive Transfer
Neoplasm Antigens
Antigens
Experimental Melanomas
Tumor Microenvironment
Green Fluorescent Proteins
Melanoma
Vaccination
Cytokines
Ligands
Cell Line
Peptides
Antibodies
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. / Blank, Christian; Brown, Ian Elliott; Peterson, Amy C.; Spiotto, Mike; Iwai, Yoshiko; Honjo, Tasuku; Gajewski, Thomas F.

In: Cancer Research, Vol. 64, No. 3, 01.02.2004, p. 1140-1145.

Research output: Contribution to journalArticle

Blank, Christian ; Brown, Ian Elliott ; Peterson, Amy C. ; Spiotto, Mike ; Iwai, Yoshiko ; Honjo, Tasuku ; Gajewski, Thomas F. / PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. In: Cancer Research. 2004 ; Vol. 64, No. 3. pp. 1140-1145.
@article{c5a20a3a32c340a9873f35aff13d7cfb,
title = "PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells",
abstract = "Although increased circulating tumor antigen-specific CD8+ T cells can be achieved by vaccination or adoptive transfer, tumor progression nonetheless often occurs through resistance to effector function. To develop a model for identifying mechanisms of resistance to antigen-specific CTLs, poorly immunogenic B16-F10 melanoma was transduced to express the K b-binding peptide SIYRYYGL as a green fluorescent protein fusion protein that should be recognized by high-affinity 2C TCR transgenic T cells. Although B16.SIY cells expressed high levels of antigen and were induced to express Kb in response to IFN-γ, they were poorly recognized by primed 2C/RAG2-/- T cells. A screen for candidate inhibitory ligands revealed elevated PD-L1/B7H-1 on IFN-γ-treated B16-F10 cells and also on eight additional mouse tumors and seven human melanoma cell lines. Primed 2C/RAG2-/-/PD-1-/- T cells showed augmented cytokine production, proliferation, and cytolytic activity against tumor cells compared with wild-type 2C cells. This effect was reproduced with anti-PD-L1 antibody present during the effector phase but not during the priming culture. Adoptive transfer of 2C/RAG2-/-/PD-1-/- T cells in vivo caused tumor rejection under conditions in which wild-type 2C cells or CTLA-4-deficient 2C cells did not reject. Our results support interfering with PD-L1/PD-1 interactions to augment the effector function of tumor antigen-specific CD8+ T cells in the tumor microenvironment.",
author = "Christian Blank and Brown, {Ian Elliott} and Peterson, {Amy C.} and Mike Spiotto and Yoshiko Iwai and Tasuku Honjo and Gajewski, {Thomas F.}",
year = "2004",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-03-3259",
language = "English (US)",
volume = "64",
pages = "1140--1145",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

AU - Blank, Christian

AU - Brown, Ian Elliott

AU - Peterson, Amy C.

AU - Spiotto, Mike

AU - Iwai, Yoshiko

AU - Honjo, Tasuku

AU - Gajewski, Thomas F.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Although increased circulating tumor antigen-specific CD8+ T cells can be achieved by vaccination or adoptive transfer, tumor progression nonetheless often occurs through resistance to effector function. To develop a model for identifying mechanisms of resistance to antigen-specific CTLs, poorly immunogenic B16-F10 melanoma was transduced to express the K b-binding peptide SIYRYYGL as a green fluorescent protein fusion protein that should be recognized by high-affinity 2C TCR transgenic T cells. Although B16.SIY cells expressed high levels of antigen and were induced to express Kb in response to IFN-γ, they were poorly recognized by primed 2C/RAG2-/- T cells. A screen for candidate inhibitory ligands revealed elevated PD-L1/B7H-1 on IFN-γ-treated B16-F10 cells and also on eight additional mouse tumors and seven human melanoma cell lines. Primed 2C/RAG2-/-/PD-1-/- T cells showed augmented cytokine production, proliferation, and cytolytic activity against tumor cells compared with wild-type 2C cells. This effect was reproduced with anti-PD-L1 antibody present during the effector phase but not during the priming culture. Adoptive transfer of 2C/RAG2-/-/PD-1-/- T cells in vivo caused tumor rejection under conditions in which wild-type 2C cells or CTLA-4-deficient 2C cells did not reject. Our results support interfering with PD-L1/PD-1 interactions to augment the effector function of tumor antigen-specific CD8+ T cells in the tumor microenvironment.

AB - Although increased circulating tumor antigen-specific CD8+ T cells can be achieved by vaccination or adoptive transfer, tumor progression nonetheless often occurs through resistance to effector function. To develop a model for identifying mechanisms of resistance to antigen-specific CTLs, poorly immunogenic B16-F10 melanoma was transduced to express the K b-binding peptide SIYRYYGL as a green fluorescent protein fusion protein that should be recognized by high-affinity 2C TCR transgenic T cells. Although B16.SIY cells expressed high levels of antigen and were induced to express Kb in response to IFN-γ, they were poorly recognized by primed 2C/RAG2-/- T cells. A screen for candidate inhibitory ligands revealed elevated PD-L1/B7H-1 on IFN-γ-treated B16-F10 cells and also on eight additional mouse tumors and seven human melanoma cell lines. Primed 2C/RAG2-/-/PD-1-/- T cells showed augmented cytokine production, proliferation, and cytolytic activity against tumor cells compared with wild-type 2C cells. This effect was reproduced with anti-PD-L1 antibody present during the effector phase but not during the priming culture. Adoptive transfer of 2C/RAG2-/-/PD-1-/- T cells in vivo caused tumor rejection under conditions in which wild-type 2C cells or CTLA-4-deficient 2C cells did not reject. Our results support interfering with PD-L1/PD-1 interactions to augment the effector function of tumor antigen-specific CD8+ T cells in the tumor microenvironment.

UR - http://www.scopus.com/inward/record.url?scp=0842325739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842325739&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-03-3259

DO - 10.1158/0008-5472.CAN-03-3259

M3 - Article

C2 - 14871849

AN - SCOPUS:0842325739

VL - 64

SP - 1140

EP - 1145

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 3

ER -